Vor Bio Appoints Dallan Murray As Chief Commercial Officer To Head Commercial Strategy

Vor Bio, a clinical-stage biotech company focused on transforming treatments for autoimmune diseases, has named Dallan Murray as its new Chief Commercial Officer, effective immediately. Murray brings with him over 25 years of experience in commercial strategy, global product launches, and customer-facing operations across leading biotech and pharmaceutical firms.

“We’re thrilled to welcome Dallan to Vor Bio at this important inflexion point. His track record of building high-performing commercial organizations and executing successful product launches will be instrumental as we prepare for potential commercialization of telitacicept and shape our broader growth strategy,” said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. 

Murray most recently served as EVP and Chief Customer Officer at Sarepta Therapeutics, where he led commercial and medical affairs operations as well as international business units. Under his leadership, Sarepta generated $1.8 billion in net product revenue in 2024 and launched groundbreaking therapies, including the first RNA and gene therapies for Duchenne muscular dystrophy. His previous leadership roles at Vertex, Gilead, Biogen, and Johnson & Johnson further reflect his broad success in product commercialization.

“Vor Bio is building a company with great potential. With telitacicept already approved in China for multiple autoimmune indications and now advancing through global Phase 3 development, I look forward to the opportunity to bring a much-needed treatment to patients around the world. I’m excited to join the team and help lay the commercial and strategic foundation for long-term success,” said Mr. Murray. 

At Vertex, he was instrumental in the launch of INCIVEK, then the fastest biotech product to reach $1 billion in sales. At Gilead, he led the launch of VIREAD for hepatitis B, and at Biogen, he played a pivotal role in the global reintroduction of TYSABRI for multiple sclerosis. Murray holds an MBA from Queen’s University and a Bachelor of Commerce from the University of Alberta.